ClearPoint Neuro's stock has performed well over the past 4 months, supported by solid business fundamentals. Despite the move higher, ClearPoint's valuation is still modest, given the company's ...

ClearPoint faces pressure from weak 2026 guidance and regulatory uncertainty, but partner therapy launches could drive ...

SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

SOLANA BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise ...

ClearPoint Neuro Inc. (NASDAQ:CLPT) shares are trading higher Wednesday after the company announced results from a Phase I-II clinical study evaluating its ClearPoint Prism Neuro Laser Therapy System.

IRVINE, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint ® Neuro Navigation System will be featured in the laser ablation hands-on ...

The combined clearance of navigation and drug delivery technologies allows Canadian neurosurgery centers to use the company’s image-guidance workflow. The approval supports ClearPoint Neuro’s strategy ...

SOLANA BEACH, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling company providing navigation and delivery to the brain, today ...

SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brai ...